HAVcR-1 involvement in cancer progression

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Hepatitis A virus cellular receptor 1 (HAVCR1) was previously known for its roles in the immune system and kidney regeneration.
• Emerging evidence highlights HAVCR1's significant involvement in cancer biology.
• HAVCR1 is overexpressed across various cancer types and interacts with key tight junction proteins.

Approach:

• Investigating the association between HAVCR1 and tight junctions, which are crucial for maintaining epithelial and endothelial homeostasis.
• Examining the role of HAVCR1 shedding and its ectodomain in promoting cancer metastasis.
• Analyzing the link between HAVCR1 ectodomain, IL-6, angiogenesis, STAT3 activation, and HIF-1α.

Key Points:

• Tight junctions are vital for preventing cancer cell dissemination, intravasation, and extravasation, thereby inhibiting metastasis.
• HAVCR1 shedding and its ectodomain production correlate with increased IL-6 levels, promoting angiogenesis via the STAT3/HIF-1α pathway.
• The HAVCR1 ectodomain shows potential as a urinary biomarker for specific cancers.

Conclusions:

• HAVCR1 plays a multifaceted role in cancer progression, including metastasis and angiogenesis.
• HAVCR1 represents a promising target for novel anti-cancer therapeutics.
• HAVCR1's potential as both a diagnostic biomarker and a therapeutic target underscores its importance in oncology.